|
| 36961816 | Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors. | | 2023 |
| 37749246 | Systematic profiling of conditional pathway activation identifies context-dependent synthetic lethalities. | | 2023 |
| 36127368 | Systematic profiling of conditional degron tag technologies for target validation studies. | Nat Commun | 2022 |
| 34853037 | Are CRISPR Screens Providing the Next Generation of Therapeutic Targets? | Cancer Res | 2021 |
| 33450197 | Targeting pan-essential genes in cancer: Challenges and opportunities. | Cancer Cell | 2021 |
| 34342224 | Discovery of a First-in-Class Inhibitor of the PRMT5-Substrate Adaptor Interaction. | J Med Chem | 2021 |
| 34358446 | Molecular basis for substrate recruitment to the PRMT5 methylosome. | Molecular Cell | 2021 |
| 34857952 | Paralog knockout profiling identifies DUSP4 and DUSP6 as a digenic dependence in MAPK pathway-driven cancers. | Nat Genet | 2021 |
| 34568836 | Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. | Nat Cancer | 2021 |
| 31059256 | Design and Discovery of <i>N</i>-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. | J Med Chem | 2020 |
| 32292577 | Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. | Oncotarget | 2020 |
| 33209191 | Targeted Covalent Inhibition of FK506 Binding Protein 35. | ACS Medicinal Chemistry Letters | 2020 |
| 32910655 | Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer. | J Med Chem | 2020 |
| 31409633 | FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer. | Mol Cancer Ther | 2019 |
| 31554815 | Metabolomic adaptations and correlates of survival to immune checkpoint blockade. | Nat Commun | 2019 |
| 31068703 | The landscape of cancer cell line metabolism. | Nat Med | 2019 |
| 30674502 | Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation. | Clinical Cancer Research | 2019 |
| 31300006 | GEMINI: a variational Bayesian approach to identify genetic interactions from combinatorial CRISPR screens. | | 2019 |
| 31342013 | Big Data Approaches for Modeling Response and Resistance to Cancer Drugs. | Annu Rev Biomed Data Sci | 2018 |
| 30443290 | The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models. | Oncotarget | 2018 |
| 30380416 | TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer. | Cell Rep | 2018 |
| 30135191 | Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53-MDM2 Inhibitor HDM201. | Cancer Res | 2018 |
| 29764854 | Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid Tumors. | Clinical Cancer Research | 2018 |
| 29343524 | Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. | Cancer Res | 2018 |
| 27840424 | Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia. | Leukemia | 2017 |
| 28351928 | Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors. | Clin Cancer Res | 2017 |
| 28916619 | Mechanism of Action and Clinical Impact of Ribociclib-Response. | Clin Cancer Res | 2017 |
| 28425916 | Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human mutant neuroblastoma cell lines and xenograft models. | eLife | 2017 |
| 28753431 | Project DRIVE: A Compendium of Cancer Dependencies and Synthetic Lethal Relationships Uncovered by Large-Scale, Deep RNAi Screening. | Cell | 2017 |
| 28329763 | The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. | Nature | 2017 |
| 28526733 | Discovery and Optimization of HKT288, a Cadherin-6-Targeting ADC for the Treatment of Ovarian and Renal Cancers. | Cancer Discov | 2017 |
| 28265066 | Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf<sup>-/-</sup> mouse model. | Proc Natl Acad Sci U S A | 2017 |
| 27852439 | Correction: A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. | Elife | 2016 |
| 27347692 | Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. | J Med Chem | 2016 |
| 27183006 | ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor. | eLife | 2016 |
| 26731447 | Correction: Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages. | PLoS ONE | 2016 |
| 26912361 | Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5. | Science | 2016 |
| 27362227 | Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. | Nature | 2016 |
| 27260157 | CRISPR Screens Provide a Comprehensive Assessment of Cancer Vulnerabilities but Generate False-Positive Hits for Highly Amplified Genomic Regions. | Cancer Discovery | 2016 |
| 27159400 | Association of MTOR Mutations With Developmental Brain Disorders, Including Megalencephaly, Focal Cortical Dysplasia, and Pigmentary Mosaicism. | JAMA Neurol | 2016 |
| 26577700 | Maximizing the Efficacy of MAPK-Targeted Treatment in PTENLOF/BRAFMUT Melanoma through PI3K and IGF1R Inhibition. | Cancer Research | 2016 |
| 27659046 | High-Order Drug Combinations Are Required to Effectively Kill Colorectal Cancer Cells. | Cancer Res | 2016 |
| 26378449 | Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages. | PLoS ONE | 2015 |
| 25849130 | Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. | Nature Medicine | 2015 |
| 25680965 | Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure. | EMBO Reports | 2015 |
| 25965177 | A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. | Elife | 2015 |
| 26657580 | TERT promoter mutations and monoallelic activation of TERT in cancer. | Oncogenesis | 2015 |
| 26479923 | High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. | Nat Med | 2015 |
| 26175413 | CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. | Cancer Cell | 2015 |
| 24608574 | Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. | Mol Cancer Ther | 2014 |